Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3635466 | 0.97 | CYP2B6 (0.35) | CYP2D6CYP2B6NPC1 | |
| SCHEMBL19101444 | 0.88 | — | — | |
| SCHEMBL6367927 | 0.88 | CYP2D6 (0.37) | CYP2D6HTT | |
| SCHEMBL3912391 | 0.79 | NPC1 (0.32) | CYP2B6NPC1 | |
| SCHEMBL3902738 | 0.79 | NCF1 (0.36) | CYP2D6 | |
| SCHEMBL28274322 | 0.77 | GAA (0.30) | — | |
| SCHEMBL482260 | 0.77 | ALDH1A1 (0.37) | HTT | |
| SCHEMBL24663779 | 0.77 | CYP2B6 (0.34) | CYP2B6NPC1 | |
| SCHEMBL29214439 | 0.75 | HTT (0.34) | NPC1HTT | |
| SCHEMBL178517 | 0.74 | CYP2B6 (0.33) | CYP2B6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019046148-A1 | MULTIPLE TRIGGER MONOMER CONTAINING PHOTORESIST COMPOSITIONS AND METHOD | ROBINSON ALEX PHILLIP GRAHAM (GB) | 2019-03-07 | — | — | WO | disclosed |
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| EP-2144909-A1 | [2, 6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122615-A1 | [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| US-5596002-A | TREATMENT OF ANTIBIOTIC RESISTANT MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142685-A1 | ORGANIC COMPOUNDS | MARK1, PKN1, MARK2 | CYP2D6 3856/4885CYP2B6 4114/4885NPC1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.